CRISPR Therapeutics AG (CRSP) News

CRISPR Therapeutics AG (CRSP): $56.24

3.36 (-5.64%)

POWR Rating

Component Grades








Add CRSP to Watchlist
Sign Up

Industry: Biotech




#297 of 347

in industry

Filter CRSP News Items

CRSP News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CRSP News Highlights

  • CRSP's 30 day story count now stands at 22.
  • Over the past 19 days, CRSP's stories per day has been in a clear downtrend, falling by about 0.18 per day.
  • The most mentioned tickers in articles about CRSP are DRUG, VRTX and GENE.

Latest CRSP News From Around the Web

Below are the latest news stories about CRISPR THERAPEUTICS AG that investors may wish to consider to help them evaluate CRSP as an investment opportunity.

AI and Automation Leaders for 2024: 7 Stocks to Stay Ahead of the Robot Uprising

It’s time for investors to ditch the search for the mythical crystal ball and instead embrace the algorithms when deciphering the best AI stock for your needs.

Josh Enomoto on InvestorPlace | December 30, 2023

3 Healthcare Technology Stocks to Improve Lives in 2024

Healthcare technology is one of 2024's top investment trends, and investors looking for long-term upside should check out these top stocks.

Jeremy Flint on InvestorPlace | December 25, 2023

Could CRISPR Therapeutics Stock Help You Become a Millionaire?

There are plenty of reasons to be optimistic about CRISPR's future.

Yahoo | December 22, 2023

Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?

The FDA's recent approval of CRISPR Therapeutics' first therapy is a step in the right direction.

Yahoo | December 22, 2023

6 Words That Explain Why CRISPR Stock Isn't Soaring Despite the Recent FDA Approval for Its Gene-Editing Therapy

Should you buy CRISPR's stock on the dip?

Yahoo | December 21, 2023

Better Bull Market Buy: CRISPR Therapeutics vs. Pfizer Stock

These stocks are currently going in different directions, but both could go up in a new bull market.

Yahoo | December 21, 2023

CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief

The fate of Crispr and CRSP stock will be determined by the success of other drugs in the company's pipeline rather than Casgevy.

Dana Blankenhorn on InvestorPlace | December 20, 2023

3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow

CRISPR Therapeutics stock has increased in the double digits this year.

Yahoo | December 20, 2023

3 Genomics Stocks to Unlock the Future of Medicine

Genomics stocks stand to surge in 2024 after the FDA approved the nation's first gene-editing therapeutic for clinical use.

Jeremy Flint on InvestorPlace | December 19, 2023

Crispr Therapeutics Medical Chief Morrow to Resign

The gene editing company said the resignation wasn’t the result of any disagreement with the company.

Yahoo | December 19, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!